Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study

Svelte® Medical Systems today announced completion of primary endpoint 6-month follow-up in DIRECT II , a prospective, randomized, multi-center clinical study comparing the safety and efficacy of the Svelte drug-eluting coronary stent Integrated Delivery System to Medtronic’s Resolute Integrity™ drug-eluting stent.



from Content Keyword RSS http://ift.tt/1nYHhiB

via IFTTT